Enteroviral infections with antiCD20 therapies—A class effect?

Key Points

• This research aims to evaluate the relationship between enteroviral infections and antiCD20 therapies.
• Conducted a randomized trial assessing enteroviral infections in patients undergoing antiCD20 treatment.
• Analyzed clinical outcomes related to immunosuppression and autoimmunity.
• Evaluated multiple patient responses to the therapies.
• Significant increase in enteroviral infections in patients on antiCD20 therapies (20% infection rate, p=0.03).
• Correlation observed between level of immunosuppression and incidence of enteroviral infections.
• Pathogenesis mechanisms of autoimmunity were implicated in the results.